Emergent BioSolutions Inc (EBS) Q4 2025 Earnings Call Highlights: Strategic Gains Amid Revenue ... [Yahoo! Finance]
Emergent Biosolutions, Inc. (EBS)
Last emergent biosolutions, inc. earnings: 4/30 04:08 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.emergentbiosolutions.com
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Release Date: February 26, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Emergent BioSolutions Inc ( NYSE:EBS ) achieved a significant reduction in net leverage from 3.3 times to 1.9 times by the end of 2025. The company reported a strong adjusted EBITDA of $205 million, marking a 12% increase year-over-year. Gross margin expanded by 900 basis points, reflecting improved operational efficiency. Emergent BioSolutions Inc ( NYSE:EBS ) secured multiple biodefense contracts, including a new multi-year agreement with the government of Canada valued at CAD 140 million. The company returned capital to shareholders through share repurchases and maintained a strong cash position with $205 million in cash by year-end. Negative Points The US government shutdown created uncertainty for some public interest customers, impacting the naloxone business. Commercial
Show less
Read more
Impact Snapshot
Event Time:
EBS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EBS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EBS alerts
High impacting Emergent Biosolutions, Inc. news events
Weekly update
A roundup of the hottest topics
EBS
News
- Emergent Biosolutions (EBS) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c-)" to "sell (d+)".MarketBeat
- Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of DirectorsGlobeNewswire
- Emergent Biosolutions Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Emergent BioSolutions outlines $720M–$760M 2026 revenue target as transformation plan advances [Seeking Alpha]Seeking Alpha
EBS
Earnings
- 10/29/25 - Beat
EBS
Analyst Actions
- 12/16/25 - HC Wainwright
EBS
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- EBS's page on the SEC website